Overview

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Status:
RECRUITING
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Phase:
PHASE1
Details
Lead Sponsor:
University of California, Davis
Collaborator:
National Institutes of Health (NIH)